David H Aggen, MD PhD· @Dr_Aggen · X·· 1 天前评分70
正文 · 原文
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy.
🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer #GUOnc @OncoAlert @BladderCancerUS
16 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源:David H Aggen, MD PhD · x.com
